|
|
|
02.11.26 - 13:12
|
ROUNDUP: IDEXX Laboratories Boost FY26 Outlook (AFX)
|
|
|
WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Monday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) raised its earnings and revenue guidance for the f......
|
|
|
02.11.26 - 13:01
|
IDEXX Laboratories Inc Q3 Profit Climbs (AFX)
|
|
|
WASHINGTON (dpa-AFX) - IDEXX Laboratories Inc (IDXX) released earnings for its third quarter that Increases, from last yearThe company's earnings totaled $317.145 million, or $4.01 per share. This......
|
|
|
|
|
|
|
02.11.26 - 12:36
|
IDEXX Laboratories Announces Third Quarter Results (Business Wire)
|
|
|
Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic.
Double-digit organic revenue growth was led by strong volume expansion, including benefits from IDEXX's innovations and excellent commercial execution.
Places over 1,900 IDEXX inVue Dx™ analyzers during the quarter, driving installed base to nearly 11,000 instruments.
Delivers EPS of $4.01, an increase of 18% as reported and 22% on a comparable basis, with operating margin up 100 basis points as reported and 60 basis points on a comparable basis.
Increases 2026 revenue guidance to $4,741 million - $4,767 million, up $32 million at midpoint, reflecting strong CAG Diagnostics recurring revenue performance.
Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.10.26 - 17:36
|
IDEXX Laboratories to Release 2026 Third Quarter Financial Results (Business Wire)
|
|
|
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.
The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 715328.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolv...
|
|
|
|
|
|
|
|
|
16.09.26 - 13:06
|
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence (Business Wire)
|
|
|
Acquisition strengthens IDEXX's connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilizationWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. Serving both multipractice corporate groups and independent veterinary practices worldwide, CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians' time. The acquisition expands the value of IDEXX's software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated int...
|
|
|
|
|
|